TY - JOUR
T1 - Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites
AU - Bates, Sarah J.
AU - Winstanley, Peter A.
AU - Watkins, William M.
AU - Alloueche, Ali
AU - Bwika, Juma
AU - Happi, T. Christian
AU - Kremsner, Peter G.
AU - Kublin, James G.
AU - Premji, Zul
AU - Sibley, Carol Hopkins
N1 - Funding Information:
Financial support: The clinical study from which these samples were derived received financial support from the United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Medicine and the UK Government Department for International Development, in partnership with GlaxoSmithKline (GSK) Pharmaceuticals; Wellcome Trust (funding to the research facilities in Kenya and Malawi and institutional support to P.A.W.); Wellcome Trust of Great Britain (grant 056305 for personal and project support to W.M.); GSK (support to A.A.); US National Institutes of Health (grants AI 42321 and AI 55604 for molecular analysis to C.H.S.).
PY - 2004/11/15
Y1 - 2004/11/15
N2 - In eastern and southern Africa, there has been a rapid increase in the prevalence of alleles with mutations in the Plasmodium falciparum dihydrofolate reductase gene (dhfr) associated with increased risk of clinical failure of sulfadoxine-pyrimethamine (S/P). Molecular methods for surveillance of these mutations are now widespread, but the usual analysis detects only the most prevalent allele in a polyclonal sample. We used a yeast-expression system to identify rare, highly pyrimethamine-resistant alleles of dhfr in isolates from 5 African countries-Kenya, Tanzania, Malawi, Gabon, and Nigeria. Only the isolates from Nigeria yielded significant numbers of novel resistant alleles, and only 1 of the alleles from any location showed a >3-fold increase in resistance to S/P or to chlorproguanil-dapsone. Overall, these results suggest that dhfr alleles that confer high levels of resistance to antifolates are rare, even in eastern and southern Africa, where pyrimethamine has been intensively used.
AB - In eastern and southern Africa, there has been a rapid increase in the prevalence of alleles with mutations in the Plasmodium falciparum dihydrofolate reductase gene (dhfr) associated with increased risk of clinical failure of sulfadoxine-pyrimethamine (S/P). Molecular methods for surveillance of these mutations are now widespread, but the usual analysis detects only the most prevalent allele in a polyclonal sample. We used a yeast-expression system to identify rare, highly pyrimethamine-resistant alleles of dhfr in isolates from 5 African countries-Kenya, Tanzania, Malawi, Gabon, and Nigeria. Only the isolates from Nigeria yielded significant numbers of novel resistant alleles, and only 1 of the alleles from any location showed a >3-fold increase in resistance to S/P or to chlorproguanil-dapsone. Overall, these results suggest that dhfr alleles that confer high levels of resistance to antifolates are rare, even in eastern and southern Africa, where pyrimethamine has been intensively used.
UR - http://www.scopus.com/inward/record.url?scp=8444219613&partnerID=8YFLogxK
U2 - 10.1086/425078
DO - 10.1086/425078
M3 - Article
C2 - 15499534
AN - SCOPUS:8444219613
SN - 0022-1899
VL - 190
SP - 1783
EP - 1792
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 10
ER -